Research

Hormonal

Combination anti-obesity medication regimens including GLP-1 receptor agonists can achieve total body weight loss (approx. 32.5%) comparable to metabolic/bariatric surgery in patients with severe obesity.

If you have severe obesity and have not lost significant weight with standard medications or lifestyle changes alone, ask your doctor about combination therapy. Adding a GLP-1 agonist (like semaglutide) to other approved weight-loss drugs may produce results similar to bariatric surgery. This approach targets multiple biological pathways (hunger, satiety, metabolism) simultaneously, which may be necessary for severe cases.

LimitedSupportsLOW confidence
This case highlights the potential benefit of combination anti-obesity medication regimens including glucagon-like peptide-1 receptor agonists, as such regimens may provide a synergistic effect by targeting multiple eating behavior pathways simultaneously... resulting in a 32.5% total body weight reduction, approximating that which can be achieved following metabolic/bariatric surgery.
Priya N Patel et al. · JCEM Case Reports · 2022

Why this rating

Based on a single case report (n=1), lacking control groups or statistical power.

Source

Weight Loss From Combination Anti-Obesity Medication Regimens Can Approach that Achieved From Bariatric Surgery

Priya N Patel et al. · JCEM Case Reports · 2022

DOI 10.1210/jcemcr/luac038

case_report · n=1Cited 4×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →